Skip to content

A clinical trial to study the effect of aqueous solution of white mustard seeds as anti-septic in patients with chronic wound.

A controlled clinical study on the anti microbial activity of Sarshapa arka for wound asepsis in Dushta vrana. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068888
Enrollment
30
Registered
2024-06-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L984- Non-pressure chronic ulcer of skin, not elsewhere classified

Interventions

None listed

Sponsors

Dr Nischintha H R
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with lakshanas of Dushta vrana . 2.Subjects with chronic non- healing wounds , features such as wounds after 7 days , putipuya , daha , paka , kandu, shopha , dushta shonita srava. 3.Subjects with wound irrespective of stage of infection. 4. Subjects irrespective of age, gender , socioeconomic status will be selected . 5. Subjects who have willingly accepted to sign the consent form.

Exclusion criteria

Exclusion criteria: 1. Any topical application over Dushta vrana at the time of collection of swab. 2. Any systemic/topical antibiotic intervention for past 1 week. 3.Open wounds involving multiple body regions.

Design outcomes

Primary

MeasureTime frame
1. Total microbial load difference – Pre and post application of Sarshapa arka and Povidone Iodine 5% solution.Timepoint: 7 days

Secondary

MeasureTime frame
1. Improvement in the quality of life 2.To assess any change in the wound by visual observation. Timepoint: 7 days

Countries

India

Contacts

Public ContactDr Nischintha H R

Shri Dharmasthala Manjunatheshwara Institute of Ayurveda and Hospital, Bengaluru

bharathidanvekar@gmail.com9886410690

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026